Objective The mortality rates for bacteremia due to Pseudomonas aeruginosa remain high. In our hospital, we performed retrospective analyses to determine risk factors for mortality among patients with bacteremia caused by P. aeruginosa. Materials and Methods This retrospective cohort study was conducted among adult patients with bacteremia due to P. aeruginosa at Jikei University Hospital. We analyzed factors, such as age, gender, underlying disease, initial antimicrobial treatment, and primary site of infection to determine which of these were predictive of mortality in patients with P. aeruginosa bacteremia. Results One hundred and thirty-four patients with P. aeruginosa bacteremia were identified between April 2003 and March 2010. The 30-day mortality rate among all patients with P. aeruginosa bacteremia was 20.9%. The most common underlying disease was leukemia (20.9%), and the most common primary site of infection was the urinary tract (24.6%). Seventy-one patients (65.7%) were treated with an appropriate initial antimicrobial regimen for P. aeruginosa bacteremia. However, these patients had similar 30-day mortality to that observed in patients not administered appropriate antibiotics. This study revealed that risk factors for the 30-day mortality were thrombocytopenia and polymicrobial P. aeruginosa bacteremia (p<0.01). Conclusion Thrombocytopenia and polymicrobial bacteremia were associated with a greater incidence of 30-day mortality among patients with P. aeruginosa bacteremia. On the other hand, age, underlying disease, and inappropriate initial empirical antimicrobial treatment did not affect mortality.
Introduction
Bloodstream infections can cause serious diseases that may be associated with significant mortality. The incidence of bloodstream infection due to gram-negative bacteria shows an upward trend and accounts for more than 40% of all bloodstream infections (1) . Among gram-negative bacteria, Pseudomonas aeruginosa accounts for 3%-7% of all bloodstream infections and 23%-26% of gram-negative bacteremia (2) (3) (4) . It is one of the most important pathogens, particularly in nosocomial infections. The frequency of P. aeruginosa infection is 3%-12% of all bacterial infections, which accounts for 25%-30% of febrile episodes in neutropenic cancer patients (5) . P. aeruginosa bacteremia occurs following various infectious conditions, including pneumonia, pancreaticobiliary tract infection, and urinary tract infection (2, 6) . In addition, mortality rates for bloodstream infections due to P. aeruginosa have remained high, leading to the introduction of antipseudomonal antibiotics.
Several investigators have shown that various factors are associated with a poor prognosis in patients with blood-stream infection, including thrombocytopenia (7), polymicrobial bacteremia (8, 9) , and septic shock (10) . In particular, some reports have indicated that inappropriate antibiotics and delay of adequate antibiotic therapy increase mortality risk in patients with bloodstream infections due to P. aeruginosa (2, 6, 11) . Several reports described risk factor analysis for mortality due to bloodstream infections including P. aeruginosa bacteremia; however, there are few data on Japanese subjects. In the present study, to determine risk factors for 30-day mortality of bloodstream infection due to P. aeruginosa, we evaluated cases of P. aeruginosa bacteremia in our hospital.
Materials and Methods

Study population
This study was performed at a hospital affiliated with the Jikei University School of Medicine; it is a 1075-bed hospital in Tokyo, Japan. This study included patients aged 20 years or more whose blood culture tested positive for P. aeruginosa between April 2003 and March 2010.
Study design
A retrospective cohort study was conducted to evaluate risk factors for 30-day mortality associated with P. aeruginosa bacteremia. We assessed the following characteristics for each patient obtained from their medical records: age, gender, presence of underlying disease, neutropenia, thrombocytopenia at the time when blood culture samples were collected, and the primary site of infection.
Definitions
The diagnosis of P. aeruginosa bacteremia was defined as the identification of P. aeruginosa in blood culture. Bacteremia was defined as polymicrobial if microorganisms other than P. aeruginosa were simultaneously recovered from the blood culture, excluding coagulase-negative staphylococci, Bacillus spp., and Propionibacterium spp., which are skin contaminants. Initial antimicrobial treatment was classified as either an appropriate or inappropriate choice of antimicrobial therapy. Appropriate choice of antimicrobial therapy was defined as administration of antipseudomonal antibiotics proven to be effective, in vitro, against P. aeruginosa isolated from blood culture. Moreover, we also evaluated the time to administration of appropriate antimicrobial treatment through blood culture sampling. Neutropenia and thrombocytopenia were defined as an absolute neutrophil count of <500/mm 3 and a platelet count of <1.0×10 5 /mm 3 , respectively.
Microbiological methods
Blood cultures, each consisting of aerobic and anaerobic samples, were processed at the clinical laboratory of our university-affiliated hospital. Identification of P. aeruginosa and antibiotic susceptibility tests were performed on a MicroScan Walk Away 96 (Dade Behring, Inc., West Sacramento, CA, USA). The Clinical Laboratory and Standards Institute criteria were used to define susceptibility or resistance to these antimicrobial agents.
Statistical analysis
The Chi-squared or Fisher's exact test was used to compare categorical variables; Student's t-test and MannWhitney U-test were used to compare continuous variables, as needed. To determine independent risk factors for 30-day mortality, a multiple logistic regression model was used to control the effects of confounding variables. The results of logistic regression analysis were reported as adjusted odds ratio (AOR) with 95% confidence interval (CI). All p-values were two-tailed and statistical significance was set at p< 0.05. We performed all statistical analyses using IBM SPSS Statistics 19 (IBM Japan, Ltd.).
Results
Clinical characteristics of patients with P. aeruginosa bacteremia
During the study period, a total of 134 patients with P. aeruginosa bacteremia were identified. Of these, 71.4% (96/ 134) were men and the mean age for all patients was 63.9± 14.3 years. Of these 134 patients, 110 had an underlying disease, leukemia being the most common (35.1%, 47/134) followed by solid tumor (29.9%, 40/134). Hematological data at the time of blood culture sampling showed that 57 of 134 patients (42.5%) had thrombocytopenia (<1.0×10 5 platelets/mm 3 ) and 39 (29.1%) had neutropenia (<500 cells/mm 3 ).
Clinical features of patients and risk factors for 30-day mortality
The 30-day mortality rate among all patients was 20.9% (28/134). We demonstrated the relationship between clinical features of patients and 30-day mortality (Table 1) . From univariate analysis, hematological disease, neutropenia, and thrombocytopenia were determined to be the underlying factors associated with 30-day mortality in P. aeruginosa bacteremia. In addition, hematocrit levels in non-survivors were significantly lower than those in survivors.
Twenty-six of 134 patients with P. aeruginosa bacteremia (19.4%) had polymicrobial bacteremia. The most frequent pathogens associated with polymicrobial P. aeruginosa bacteremia, excluding coagulase-negative staphylococci and Bacillus spp., were Enterococcus faecalis (23.1%, 6/26) followed by Klebsiella pneumoniae (19.2%, 5/26) ( Table 2) . Thirty-day mortality in patients with polymicrobial P. aeruginosa bacteremia (42.3%, 11/26) was significantly higher compared to that in patients with monomicrobial bacteremia (15.7%, 17/108) (p=0.006). 
Relationship between characteristics of bacterial infection and 30-day mortality
As shown in Table 3 , the source of infection was identified in 86 of 134 patients (64.2%). The most common primary site of infection was the urinary tract (24.6%, 33/134), followed by catheter-related bloodstream infection (19.4%, 26/134). We found that the intestinal tract and soft tissues as portal sites were associated with a poor prognosis for P. aeruginosa bacteremia.
Analysis of prognostic factors in logistic regression analysis
The results of univariate analysis revealed that hematologic disease, low levels of hematocrit, neutropenia, thrombocytopenia, and polymicrobial bloodstream infection were significant variables in relation to mortality. These variables were subjected to multivariate analysis, but the source of infection was excluded from this analysis because, in many cases (35.8%), a portal site of bacteremia was not detected. From the multivariate analysis using a logistic regression model, independent risk factors for 30-day mortality were determined to be thrombocytopenia (AOR =8.311; 95% CI =2.283-30.249; p<0.001) and polymicrobial P. aeruginosa bacteremia (AOR =4.664; 95% CI =1.504-14.458; p<0.008) ( Table 4) .
Thrombocytopenia was one of the common findings in patients with hematologic diseases, and 38 of 57 patients with thrombocytopenia (66.7%) had hematologic disease in the present study. Therefore, we investigated whether thrombocytopenia is a risk factor for 30-day mortality, even when we separated patients into those with and without hematologic disease. In patients with hematologic disease, 38 of 47 had thrombocytopenia. The rate of thrombocytopenia in the survivors with hematologic disease (23/32, 71.9%) was significantly lower than that in non-survivors (15/15, 100%; p=0.021). Similarly, in patients without hematologic disease, the rate of thrombocytopenia in survivors (11/74 patients, 14.9%) was lower than that in non-survivors (8/13, 61.5%; p=0.001). These results indicate that thrombocytopenia is one of the risk factors for 30-day mortality in patients with and without hematologic disease.
On the other hand, the poor prognosis in patients with polymicrobial bacteremia might be due to other bacterial species isolated with P. aeruginosa. To determine whether appropriate antibiotics improved the prognosis, we investigated the antibiotics administered to patients with polymicrobial bacteremia. Ten of 26 patients (38.5%) were administered appropriate antibiotics for both P. aeruginosa and other bacterial species within 24 h, and their mortality rate was 30.0% (3/10). On the other hand, the mortality rate in patients not administered appropriate antibiotics for either P. aeruginosa or other bacterial species was 50.0% (8/16). However, this mortality rate was not significantly different between the two groups (p=0.277).
Relationship between mortality and appropriate antibiotics
Tam et al demonstrated that multidrug resistance was one of the significant risk factors for 30-day mortality in patients with P. aeruginosa bacteremia (12) . In the present study, only one patient had bacteremia due to multidrug-resistant P. aeruginosa, and he died within 30 days of the onset of P. aeruginosa bacteremia. One of the reasons for the poor prognosis in multidrug-resistant P. aeruginosa bacteremia is the delay in the administration of appropriate antibiotics. To determine the relationship between mortality and appropriate antibiotics, we evaluated the antibiotics administered only in patients with monomicrobial bacteremia (9) . In total, 62, 71, and 81 patients (57.4%, 65.7%, and 75.0%) were administered appropriate antimicrobial therapy for P. aeruginosa bacteremia within 12, 24, and 48 h, respectively, of the onset of bacteremia. The following antimicrobial therapies were used: single carbapenem (n=41), single cephalosporin (n=18), single fluoroquinolone (n=6), antipseudomonal penicillin (n=3), monobactam (n=1), and combination therapy with an aminoglycoside (n=2). There were no significant differences among any of the therapies affecting 30-day mortality.
Several studies have indicated that appropriate antimicrobial treatment improves the prognosis of bloodstream infection (2, 6, 11). As shown in Table 5 , we found no relationship between time, appropriate choice of antimicrobial therapy, and 30-day mortality. To investigate the reasons for these results, we compared the background between the appropriate and inappropriate antimicrobial treatment groups within 24 h of the onset of bacteremia. As shown in Table 6, there were more patients with hematologic diseases and patients administered immunosuppressive agents in the appropriate treatment group than in the inappropriate treatment group. In addition, the number of cases with neutropenia or thrombocytopenia in the appropriate treatment group was significantly higher than that in the inappropriate treatment group. These results demonstrate that the reason we could not find a relationship between the antibiotics and the prognosis in P. aeruginosa bacteremia was because patients with poor prognostic factors were treated with appropriate antibiotics.
Discussion
One of the reasons why P. aeruginosa bacteremia can develop into a critical illness is that it often occurs in an immunocompromised host as a nosocomial infection. In this study, 82.8% of subjects with P. aeruginosa bacteremia had some underlying disease, which could have left them immunocompromised. We showed that the 30-day mortality rate for P. aeruginosa bacteremia was 20.9% (28/134), which is similar to that reported in other studies (2, 6, 9, 11) . In previous studies, while the mechanism of thrombocytopenia in sepsis was not well understood, sepsis was identified as an independent risk factor for thrombocytopenia (13, 14) . The incidence rate of thrombocytopenia was 42.5% in our study, similar to that found in previous studies where the incidence of thrombocytopenia in intensive care units was reported to be in the range of 23%-43.5% (7, (13) (14) (15) . Several reports have demonstrated that in intensive care units, the mortality rate in patients with thrombocytopenia was significantly higher than in those without thrombocytopenia (7, (13) (14) (15) . In addition, other studies have indicated that thrombocytopenia is one of the prognostic factors for bacteremia, caused by Stenotrophomonas maltophilia (16) . In the present study, we also demonstrated that thrombocytopenia is a risk factor associated with mortality in P. aeruginosa bacteremia. However, we did not evaluate the relationship of the prognosis with DIC (disseminated intravascular coagulation), since data for the evaluation of DIC were unavailable in many cases. Several investigators showed DIC to be an independent poor prognostic factor in bacteremia (17, 18) . The present results indicate the possibility that thrombocytopenia and DIC could be poor prognostic factors in critically ill patients, including gram-negative bacteremia.
Several studies have demonstrated that the incidence rate of polymicrobial bloodstream infection was 12%-14% of all bacteremia (8, 19) . On the other hand, Lee and Liu demonstrated that 45.2% of Morganella morganii bacteremia was polymicrobial (20) , suggesting that the frequency of polymicrobial bacteremia varies according to pathogens. The incidence of polymicrobial bacteremia in our study was 19.4%, which is similar to that recorded by other studies on P. aeruginosa bacteremia (9, 21) . In addition, many investigators have indicated that polymicrobial bacteremia is one of the risk factors for poor prognosis (8, 9, 19, 22) . We also found that mortality among patients with polymicrobial bacteremia was significantly higher than that among patients with monomicrobial bacteremia and that polymicrobial bacteremia was an independent factor for a poor prognosis.
Previous studies have demonstrated that inappropriate antimicrobial treatment of bloodstream infections with P. aeruginosa is a poor prognostic factor (2, 6, 11) . In the present study, although 71 of 108 patients (65.7%) received appropriate antibiotic therapy within 24 h of acquisition of blood culture samples, the mortality rate was 19.7% (14/71), which is not significantly different from that of patients treated with inappropriate antibiotic therapy. One of the reasons for this result is that, as shown in Table 6 , patients with poor prognostic factors were treated with appropriate antibiotics. It cannot be denied that appropriate antibiotics improve the prognosis of P. aeruginosa bacteremia when the clinical characteristics of patients treated with appropriate antibiotics are similar to those with inappropriate antibiotics. On the other hand, we defined appropriate treatment as being when patients were administered antipseudomonal antibiotics proven effective in vitro, but we could not evaluate the antibiotic dosage because the appropriate dosage varies among Japanese guidelines. Zelenitsky et al indicated that antibiotic pharmacodynamics is associated with treatment response in P. aeruginosa bacteremia (23) . Different dosages of antipseudomonal agents might have been related to the prognosis during P. aeruginosa bacteremia in the present study. Therefore, to clarify whether appropriate antibiotics improve the prognosis of P. aeruginosa bacteremia, we have to investigate them among patients with the same clinical baselines and it is necessary to use a unified antibiotic regimen. The most important limitation of our study is that it was retrospective; therefore, primary sites of infection were determined by medical records, laboratory data, and radiological examination at the time of treatment. Consequently, there were many cases (35.8%) where the portal site of bacteremia was not determined.
In conclusion, bloodstream infection caused by P. aeruginosa is a critical illness with a high mortality. Our results showed that thrombocytopenia and polymicrobial P. aeruginosa influenced the prognosis for P. aeruginosa bacteremia. These results are similar to those of our preliminary study (24) . However, we were not able to demonstrate that mortality was improved by appropriate treatment. Therefore, a future large-scale, multicenter, prospective study is needed to accurately identify the factors predictive of improved outcomes.
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